Company Updates

ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

SGN-CD123A is a novel ADC targeted to CD123 utilizing Seattle Genetics' proprietary technology. CD123 is expressed across AML subtypes, including on leukemic stem cells, which are difficult to kill and may be responsible for high relapse rates even following intensive therapy.

Ride with me and tell others about Obliteride. Because while riding Obliteride might be hard, it's nothing compared to fighting cancer.

If you're looking for a career and not just any old job, set your sights on a company that invests in its employees by offering training and development programs. Research shows both companies and employees reap the benefits, including increased job satisfaction levels, internal promotion opportunities and better retention.

The Phase 3 Study, Called CASCADE, will Evaluate 33A in Combination with Hypomethylating Agents in Older AML Patients- -Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial- -Additional 33A Phase 1 Data to be Featured in an Oral Presentation at the European Hematology Association Congress in June 2016- BOTHELL, Wash.--(BUSINESS WIRE)--May 25, 2016--Seattle Genetics, Inc.

Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate- -Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Demonstrate a Three-Year Overall Survival Rate of 80 Percent, with Estimated Median Progression-Free Survival Not Yet Reached- ORLANDO, Fla.--(BUSINESS WIRE)--Dec.

Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy- -Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL- -ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials- ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 7, 2015--Seattle Genetics, Inc.